|
Midatech Pharma PLC - Cardiff-based biotechnology company focused on improving the bio-delivery and biodistribution of medicines - Receives fast track designation from the US Food & Drug Administration for its development programme of MTX110 for the treatment of recurrent glioblastoma.
Chief Scientific Officer Dmitry Zamoryakhin says: ‘rGBM is a devastating cancer marked by short survival rate and universal recurrence. Receiving fast track designation for MTX110 is an important milestone for the development of the drug as it demonstrates the need for novel and effective treatment options for this currently universally fatal disease.
‘MTX110, our water-soluble formulation of Panobinostat, will soon start recruitment into a company-sponsored phase 1 study in patients with recurrent GBM.’
Current stock price: up 46% at 14.87 pence on Wednesday afternoon
12-month-change: down 45%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
